Lupin secures non-exclusive license with Takeda for Vonoprazan tablets in India.

Lupin Limited has secured a non-exclusive patent licensing agreement with Takeda Pharmaceutical to market Vonoprazan tablets in India under the brand name Lupivon. The drug, a potassium-competitive acid blocker, will be available in 10 mg and 20 mg doses for treating various gastrointestinal conditions. This partnership aims to address significant healthcare needs in India, where acid peptic disorders are prevalent. Following the announcement, Lupin's stock fell by 1.97%.

September 18, 2024
6 Articles